

APAC, MENA, and Africa Sickle Cell Anemia Market Research Report Information By Treatment (Pharmacotherapy, Blood Transfusion, Bone Marrow Transplant, and Gene Therapy), by End User (Hospitals, Specialty Clinics, and Others), by Region Forecast to 2032

Market Report | 2024-08-02 | 108 pages | Market Research Future

AVAILABLE LICENSES:

- Single User Price \$2950.00
- Enterprisewide Price \$5250.00

Report description:

APAC, MENA, and Africa Sickle Cell Anemia Market Research Report Information By Treatment (Pharmacotherapy, Blood Transfusion, Bone Marrow Transplant, and Gene Therapy), by End User (Hospitals, Specialty Clinics, and Others), by Region Forecast to 2032

Market Overview

APAC, MENA, and Africa Sickle Cell Anemia Market is anticipated to register a notable CAGR of 14.77% during the review period. Sickle Cell Anemia is a genetic disorder that primarily affects red blood cells. It is caused by a mutation in the HBB gene, leading to the production of abnormal hemoglobin, called hemoglobin S. This causes red blood cells to become rigid and sickle-shaped, which can obstruct blood flow and cause various health complications.

The growing government support and policies associated with sickle cell anemia, and increased prevalence of sickle cell anemia increases the demand for drug treatment are major factors driving the growth of the APAC, MENA, and Africa. However, the high cost of bone marrow transplants and the side effects associated with drug treatment are expected to restrain the growth of the market. Nevertheless, the government is forming partnerships with manufacturers to produce affordable sickle cell disease medications and advancements in treatment options, which is attributed to creating lucrative opportunities for the players operating in the APAC, MENA, and Africa market.

Market Segmentation

Based on end user, the APAC, MENA, and Africa sickle cell anemia market is segmented into hospitals, specialty clinics, and others. The hospitals segment dominated the market in 2022, while the specialty clinics segment is projected to be the fastest-growing segment during the forecast period, 2023-2032.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Based on treatment, the APAC, MENA, and Africa Sickle Cell Anemia market has been segmented into pharmacotherapy, blood transfusion, bone marrow transplant, and gene therapy. The blood transfusion segment dominated the market in 2022, while the gene therapy segment is projected to be the fastest-growing segment during the forecast period, 2023-2032.

Based on region, the APAC, MENA, and Africa sickle cell anemia market has been segmented into Asia-Pacific, Middle East & North Africa, Africa. Asia-Pacific accounted for the largest market share in 2022 and is anticipated to reach USD 4,220.86 million by 2032, registering a CAGR of 16.31% during the forecast period. However, Asia-Pacific is projected to grow at the highest CAGR of 16.31% during the forecast period.

Major Players

The key players operating in the APAC, MENA, and Africa Sickle Cell Anemia market are Pfizer Inc, Cipla Ltd., Novartis AG, Emmaus Medical, Inc, Zydus Group, Vertex Pharmaceuticals Incorporated, and Nestle.

Table of Contents:

TABLE OF CONTENTS

1	EXECUTIVE SUMMARY	16
2	MARKET INTRODUCTION	18
2.1	DEFINITION	18
2.2	SCOPE OF THE STUDY	18
2.3	RESEARCH OBJECTIVE	18
2.4	MARKET STRUCTURE	18
3	RESEARCH METHODOLOGY	19
3.1	OVERVIEW	19
3.2	DATA FLOW	22
3.2.1	DATA MINING PROCESS	22
3.3	PURCHASED DATABASE:	23
3.4	SECONDARY SOURCES:	24
3.4.1	SECONDARY RESEARCH DATA FLOW:	25
3.5	PRIMARY RESEARCH:	26
3.5.1	PRIMARY RESEARCH DATA FLOW:	27
3.5.2	PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED	28
3.6	APPROACHES FOR MARKET SIZE ESTIMATION:	29
3.6.1	REVENUE ANALYSIS APPROACH	29
3.7	DATA FORECASTING	30
3.7.1	DATA FORECASTING TECHNIQUE	30
3.8	DATA MODELING	31
3.8.1	MICROECONOMIC FACTOR ANALYSIS:	31
3.8.2	DATA MODELING:	32
3.9	TEAMS AND ANALYST CONTRIBUTION	33
4	MARKET DYNAMICS	35
4.1	INTRODUCTION	35
4.2	DRIVERS	36
4.2.1	GROWING GOVERNMENT SUPPORT AND POLICIES ASSOCIATED WITH SICKLE CELL ANAEMIA	36
4.2.2	INCREASED PREVALENCE OF SICKLE CELL ANEMIA INCREASES THE DEMAND FOR DRUG TREATMENT	36
4.3	RESTRAINTS	37
4.3.1	HIGH COST OF BONE MARROW TRANSPLANT AND SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT	37
4.4	OPPORTUNITY	38
4.4.1	GOVERNMENT IS FORMING PARTNERSHIPS WITH MANUFACTURERS TO PRODUCE AFFORDABLE SICKLE CELL DISEASE	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

MEDICATIONS	38
4.4.2 ADVANCEMENTS IN TREATMENT OPTIONS	39
5 MARKET FACTOR ANALYSIS	40
5.1 PORTER'S FIVE FORCES MODEL	40
5.1.1 THREAT OF NEW ENTRANTS	40
5.1.2 BARGAINING POWER OF SUPPLIERS	41
5.1.3 THREAT OF SUBSTITUTES	41
5.1.4 BARGAINING POWER OF BUYERS	41
5.1.5 INTENSITY OF RIVALRY	41
5.2 IMPACT OF COVID-19 ON THE APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET	42
5.3 GLOBAL REVENUE OF MAJOR BRANDS	42
6 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, BY TREATMENT	43
6.1 INTRODUCTION	43
6.2 PHARMACOTHERAPY	45
6.3 BLOOD TRANSFUSION	45
6.4 BONE MARROW TRANSPLANT	45
6.5 GENE THERAPY	46
7 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, BY END USER	47
7.1 INTRODUCTION	47
7.2 HOSPITALS	49
7.3 SPECIALTY CLINICS	49
7.4 OTHERS	49
8 APAC, MENA, AND AFRICA SICKLE CELL ANEMIA MARKET, BY REGION	50
8.1 OVERVIEW	50
8.2 ASIA-PACIFIC	51
8.2.1 CHINA	53
8.2.2 INDIA	54
8.2.3 JAPAN	55
8.2.4 AUSTRALIA	55
8.2.5 SOUTH KOREA	56
8.2.6 REST OF ASIA-PACIFIC	57
8.3 MIDDLE EAST & NORTH AFRICA	58
8.3.1 UAE	61
8.3.2 EGYPT	61
8.3.3 SAUDI ARABIA	62
8.3.4 KUWAIT	63
8.3.5 QATAR	63
8.3.6 OMAN	64
8.3.7 IRAN	65
8.3.8 JORDAN	65
8.3.9 REST OF MENA	66
8.4 AFRICA	67
8.4.1 SOUTH AFRICA	69
8.4.2 ETHIOPIA	70
8.4.3 NIGERIA	70
8.4.4 REST OF AFRICA	71
9 COMPETITIVE LANDSCAPE	73

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

9.1	INTRODUCTION	73
9.2	MARKET SHARE ANALYSIS, 2022	73
9.3	COMPETITOR DASHBOARD	74
9.4	PUBLIC PLAYERS STOCK SUMMARY	75
9.5	COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL	75
9.6	KEY DEVELOPMENTS & GROWTH STRATEGIES	76
9.6.1	PRODUCT LAUNCH / PRODUCT APPROVAL	76
9.6.2	AGREEMENT	76
10	COMPANY PROFILES	77
10.1	PFIZER INC	77
10.1.1	COMPANY OVERVIEW	77
10.1.2	FINANCIAL OVERVIEW	78
10.1.3	PRODUCTS OFFERED	78
10.1.4	KEY DEVELOPMENTS	79
10.1.5	SWOT ANALYSIS	79
10.1.6	KEY STRATEGIES	80
10.2	EMMAUS MEDICAL, INC	81
10.2.1	COMPANY OVERVIEW	81
10.2.2	FINANCIAL OVERVIEW	82
10.2.3	PRODUCTS OFFERED	82
10.2.4	KEY DEVELOPMENTS	83
10.2.5	SWOT ANALYSIS	83
10.2.6	KEY STRATEGIES	84
10.3	NOVARTIS AG	85
10.3.1	COMPANY OVERVIEW	85
10.3.2	FINANCIAL OVERVIEW	86
10.3.3	PRODUCTS OFFERED	87
10.3.4	KEY DEVELOPMENTS	87
10.3.5	SWOT ANALYSIS	87
10.3.6	KEY STRATEGIES	88
10.4	CIPLA LTD	89
10.4.1	COMPANY OVERVIEW	89
10.4.2	FINANCIAL OVERVIEW	90
10.4.3	PRODUCTS OFFERED	90
10.4.4	KEY DEVELOPMENTS	90
10.4.5	SWOT ANALYSIS	91
10.4.6	KEY STRATEGIES	91
10.5	NESTLE	92
10.5.1	COMPANY OVERVIEW	92
10.5.2	FINANCIAL OVERVIEW	93
10.5.3	PRODUCTS OFFERED	93
10.5.4	KEY DEVELOPMENTS	94
10.5.5	KEY STRATEGIES	94
10.6	ZYDUS GROUP	95
10.6.1	COMPANY OVERVIEW	95
10.6.2	FINANCIAL OVERVIEW	96
10.6.3	PRODUCTS OFFERED	96

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

10.6.4	KEY DEVELOPMENTS	96
10.6.5	SWOT ANALYSIS	97
10.6.6	KEY STRATEGIES	97
10.7	SALIUS PHARMA PVT. LTD.	98
10.7.1	COMPANY OVERVIEW	98
10.7.2	FINANCIAL OVERVIEW	98
10.7.3	PRODUCTS OFFERED	98
10.7.4	KEY DEVELOPMENTS	99
10.7.5	KEY STRATEGIES	99
10.8	VERTEX PHARMACEUTICALS INCORPORATED	100
10.8.1	COMPANY OVERVIEW	100
10.8.2	FINANCIAL OVERVIEW	101
10.8.3	PRODUCTS OFFERED	101
10.8.4	KEY DEVELOPMENTS	101
10.8.5	SWOT ANALYSIS	102
10.8.6	KEY STRATEGIES	102
10.9	TAJ PHARMACEUTICALS LIMITED	103
10.9.1	COMPANY OVERVIEW	103
10.9.2	FINANCIAL OVERVIEW	103
10.9.3	PRODUCTS OFFERED	103
10.9.4	KEY DEVELOPMENTS	104
10.9.5	KEY STRATEGIES	104
10.10	CELON LABS	105
10.10.1	COMPANY OVERVIEW	105
10.10.2	FINANCIAL OVERVIEW	105
10.10.3	PRODUCTS OFFERED	105
10.10.4	KEY DEVELOPMENTS	106
10.10.5	KEY STRATEGIES	106

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

APAC, MENA, and Africa Sickle Cell Anemia Market Research Report Information By Treatment (Pharmacotherapy, Blood Transfusion, Bone Marrow Transplant, and Gene Therapy), by End User (Hospitals, Specialty Clinics, and Others), by Region Forecast to 2032

Market Report | 2024-08-02 | 108 pages | Market Research Future

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scott's-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$2950.00
	Enterprisewide Price	\$5250.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scott's-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-03-09"/>

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scott's-international.com

www.scott's-international.com

Signature

An empty rectangular box with a thin black border, intended for a signature.